Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Frederich

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Cardiovascular Diabetology|January 18, 2012
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular dataMichael E Cobble, Robert Frederich
Therapeutic Innovation & Regulatory Science|October 7, 2023
Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved DropoutsShuai Wang, Robert Frederich, James P Mancuso
The Journal of Laboratory and Clinical Medicine|March 29, 2002
Leptin in anorexia nervosa and bulimia nervosa: importance of assay technique and method of interpretationRobert Frederich, Shousheng Hu, Nancy Raymond, et al.
BMC Endocrine Disorders|February 26, 2014
A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapyJudith L White, Patricia Buchanan, Jia Li, et al.
Postgraduate Medicine|June 11, 2013
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trialsWilliam Cook, Brian Bryzinski, Jill Slater, et al.
Cardiovascular Diabetology|February 5, 2014
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trialsNayyar Iqbal, Artist Parker, Robert Frederich, et al.
Diabetology & Metabolic Syndrome|July 26, 2012
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trialRobert Frederich, Robert McNeill, Niklas Berglind, et al.
Diabetes & Vascular Disease Research|May 13, 2011
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitusPriscilla L Hollander, Jia Li, Robert Frederich, et al.
Clinical Interventions in Aging|April 30, 2013
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitusChetan S Karyekar, Shoba Ravichandran, Elsie Allen, et al.
Clinical Pharmacology in Drug Development|April 25, 2018
Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different DevicesEllen Q Wang, Anna Plotka, Joanne Salageanu, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Cardiovascular Diabetology|January 18, 2012
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular dataMichael E Cobble, Robert Frederich
Therapeutic Innovation & Regulatory Science|October 7, 2023
Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved DropoutsShuai Wang, Robert Frederich, James P Mancuso
The Journal of Laboratory and Clinical Medicine|March 29, 2002
Leptin in anorexia nervosa and bulimia nervosa: importance of assay technique and method of interpretationRobert Frederich, Shousheng Hu, Nancy Raymond, et al.
BMC Endocrine Disorders|February 26, 2014
A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapyJudith L White, Patricia Buchanan, Jia Li, et al.
Postgraduate Medicine|June 11, 2013
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trialsWilliam Cook, Brian Bryzinski, Jill Slater, et al.
Cardiovascular Diabetology|February 5, 2014
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trialsNayyar Iqbal, Artist Parker, Robert Frederich, et al.
Diabetology & Metabolic Syndrome|July 26, 2012
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trialRobert Frederich, Robert McNeill, Niklas Berglind, et al.
Diabetes & Vascular Disease Research|May 13, 2011
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitusPriscilla L Hollander, Jia Li, Robert Frederich, et al.
Clinical Interventions in Aging|April 30, 2013
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitusChetan S Karyekar, Shoba Ravichandran, Elsie Allen, et al.
Clinical Pharmacology in Drug Development|April 25, 2018
Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different DevicesEllen Q Wang, Anna Plotka, Joanne Salageanu, et al.
Pageof 4